Celcuity’s (CELC) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Celcuity (NASDAQ:CELCFree Report) in a research note published on Thursday morning, Benzinga reports. HC Wainwright currently has a $27.00 price objective on the stock. HC Wainwright also issued estimates for Celcuity’s FY2028 earnings at $4.08 EPS.

Other research analysts have also recently issued reports about the company. Needham & Company LLC reaffirmed a buy rating and set a $24.00 price objective on shares of Celcuity in a research report on Thursday. Craig Hallum upped their price target on Celcuity from $20.00 to $25.00 and gave the company a buy rating in a report on Thursday, March 28th. Finally, Stifel Nicolaus began coverage on shares of Celcuity in a report on Thursday, February 22nd. They set a buy rating and a $40.00 price objective on the stock.

Read Our Latest Research Report on CELC

Celcuity Stock Down 5.1 %

Shares of NASDAQ:CELC opened at $16.76 on Thursday. Celcuity has a fifty-two week low of $8.39 and a fifty-two week high of $22.19. The firm’s 50 day moving average price is $17.95 and its 200 day moving average price is $15.66. The company has a quick ratio of 13.43, a current ratio of 11.23 and a debt-to-equity ratio of 0.28. The stock has a market cap of $523.41 million, a price-to-earnings ratio of -6.03 and a beta of 0.87.

Celcuity (NASDAQ:CELCGet Free Report) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.06. As a group, equities research analysts predict that Celcuity will post -2.93 earnings per share for the current fiscal year.

Institutional Trading of Celcuity

Several institutional investors and hedge funds have recently made changes to their positions in CELC. Baker BROS. Advisors LP increased its position in Celcuity by 189.9% during the first quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company’s stock worth $33,534,000 after buying an additional 1,017,000 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Celcuity during the first quarter worth approximately $3,545,000. Vanguard Group Inc. grew its position in shares of Celcuity by 1.0% during the first quarter. Vanguard Group Inc. now owns 828,597 shares of the company’s stock worth $17,898,000 after acquiring an additional 7,821 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Celcuity by 78.5% in the 1st quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock valued at $193,000 after acquiring an additional 3,930 shares during the period. Finally, Perceptive Advisors LLC purchased a new stake in Celcuity in the 4th quarter valued at $21,583,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

About Celcuity

(Get Free Report)

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

Featured Articles

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.